Villy Valcheva
Vermögen: - $ am 31.07.2026
Vermögen: - $ am 31.07.2026
Velichka Valcheva is currently Chief Executive Officer at GH Research Plc since 2024.
Formerly, Dr. Valcheva was VP & Head-International Medical Affairs at Albireo Pharma, Inc. from 2020 to 2023 and Global Senior Medical Director-Oncology at Ipsen Pharma SAS from 2018 to 2020.
Education includes a doctorate from Medical University of Plovdiv and a graduate degree from Trinity College Dublin.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GH RESEARCH PLC -.--% | 18.03.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| GH RESEARCH PLC | Vorstandsvorsitzender | 03.09.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | 01.01.2023 |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01.01.2020 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Trinity College Dublin
Trinity College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Medical University of Plovdiv
Medical University of Plovdiv Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GH Research Plc
GH Research Plc Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapies for the management of psychiatric and neurological disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen